7-tert-butyl-2-propan-2-yl-1H-indole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 7-tert-butyl-2-propan-2-yl-1H-indole
• 化学式: C₁₅H₂₁N
• 分子量: 215.33
• InChiKey: GCBPPYFDMIAXNC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  15.8
• 氢给体数：
  1
• 氢受体数：
  0

文献信息

• LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
  申请人：INTERMUNE, INC.

  公开号：US20140200215A1

  公开（公告）日：2014-07-17

  Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

  提供的是化合物、制造这些化合物的方法、包含这些化合物的药物组合物和药品，以及使用这些化合物来治疗、预防或诊断与一个或多个溶血磷脂酸受体相关的疾病、失调或状况的方法。
• BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same
  申请人：AbbVie Inc.

  公开号：US20200239553A1

  公开（公告）日：2020-07-30

  Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.
• ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
  申请人：AbbVie Inc.

  公开号：US20200338209A1

  公开（公告）日：2020-10-29

  The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.